Literature DB >> 15018844

Mechanisms of cell death in polyglutamine expansion diseases.

Marta M Lipinski1, Junying Yuan.   

Abstract

Abnormal protein aggregation is a hallmark of many neurodegenerative diseases. However, the mechanism by which protein aggregates induce neurodegneration remains controversial. Recently proposed mechanisms of neuronal death in polyglutamine expansion diseases include activation of caspases and associated cell death pathways, interference with transcriptional regulation, downregulation of survival pathways and obstruction of axonal transport. Because the expression of expanded polyglutamine in selected neuronal populations can adversely affect multiple aspects of neuronal survival and function, we propose that effective therapeutic approaches might have to target the upstream mechanism of neurotoxicity by selectively inhibiting the formation of intraneuronal aggregates and increasing the degradation of mutant proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15018844     DOI: 10.1016/j.coph.2003.09.008

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  14 in total

Review 1.  Current understanding on the pathogenesis of polyglutamine diseases.

Authors:  Xiao-Hui He; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

Review 2.  Autophagy in health and disease: a double-edged sword.

Authors:  Takahiro Shintani; Daniel J Klionsky
Journal:  Science       Date:  2004-11-05       Impact factor: 47.728

3.  Downregulation of NF-kappaB signaling by mutant huntingtin proteins induces oxidative stress and cell death.

Authors:  Sami Reijonen; Jyrki P Kukkonen; Alise Hyrskyluoto; Jenny Kivinen; Minna Kairisalo; Nobuyuki Takei; Dan Lindholm; Laura Korhonen
Journal:  Cell Mol Life Sci       Date:  2010-03-17       Impact factor: 9.261

4.  Role of protein misfolding in DFNA9 hearing loss.

Authors:  Jianhua Yao; Bénédicte F Py; Hong Zhu; Jianxin Bao; Junying Yuan
Journal:  J Biol Chem       Date:  2010-03-12       Impact factor: 5.157

Review 5.  The pathogenesis of spinocerebellar ataxia.

Authors:  Arnulf H Koeppen
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

6.  Genetic association analyses of PHOX2B and ASCL1 in neuropsychiatric disorders: evidence for association of ASCL1 with Parkinson's disease.

Authors:  Masayuki Ide; Kazuo Yamada; Tomoko Toyota; Yoshimi Iwayama; Yuichi Ishitsuka; Yoshio Minabe; Kazuhiko Nakamura; Nobutaka Hattori; Takashi Asada; Yoshikuni Mizuno; Norio Mori; Takeo Yoshikawa
Journal:  Hum Genet       Date:  2005-07-14       Impact factor: 4.132

Review 7.  Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias.

Authors:  Antoni Matilla-Dueñas; Ivelisse Sánchez; Marc Corral-Juan; Antoni Dávalos; Ramiro Alvarez; Pilar Latorre
Journal:  Cerebellum       Date:  2010-06       Impact factor: 3.847

8.  HSP70 interacting protein prevents the accumulation of inclusions in polyglutamine disease.

Authors:  Joanna L Howarth; Colin P J Glover; James B Uney
Journal:  J Neurochem       Date:  2009-02       Impact factor: 5.372

Review 9.  Spinocerebellar ataxias caused by polyglutamine expansions: a review of therapeutic strategies.

Authors:  Benjamin R Underwood; David C Rubinsztein
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

10.  Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias.

Authors:  A Matilla-Dueñas; T Ashizawa; A Brice; S Magri; K N McFarland; M Pandolfo; S M Pulst; O Riess; D C Rubinsztein; J Schmidt; T Schmidt; D R Scoles; G Stevanin; F Taroni; B R Underwood; I Sánchez
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.